Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.

The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.

Cardiologist Gregg Fonarow, MD, reviewed decades of data and discussed the long-term impact of the AHA's Get With The Guidelines-Stroke program.

Naples Comprehensive Health is building up what it hopes will be a nationally recognized cardiology program. Robert Cubeddu, MD, and Dee Dee Wang, MD, spoke with Cardiovascular Business about the journey so far. 

Researchers focused on data from nearly 78,000 adults with cardiometabolic disorders, sharing their findings at ACC.25 in Chicago.

"We wanted to ensure that every interventionalist, regardless of location or resources, has access to the best information possible," one co-author said. 

Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.

Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.